KR101976218B1 - 4-히드록시부티르산 중수소화 유사체 - Google Patents

4-히드록시부티르산 중수소화 유사체 Download PDF

Info

Publication number
KR101976218B1
KR101976218B1 KR1020137024419A KR20137024419A KR101976218B1 KR 101976218 B1 KR101976218 B1 KR 101976218B1 KR 1020137024419 A KR1020137024419 A KR 1020137024419A KR 20137024419 A KR20137024419 A KR 20137024419A KR 101976218 B1 KR101976218 B1 KR 101976218B1
Authority
KR
South Korea
Prior art keywords
compound
formula
delete delete
sleep
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137024419A
Other languages
English (en)
Korean (ko)
Other versions
KR20140008391A (ko
Inventor
로저 디. 퉁
아담 모르간
아이. 로버트 실버맨
Original Assignee
콘서트 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘서트 파마슈티컬즈, 인크. filed Critical 콘서트 파마슈티컬즈, 인크.
Publication of KR20140008391A publication Critical patent/KR20140008391A/ko
Application granted granted Critical
Publication of KR101976218B1 publication Critical patent/KR101976218B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/115—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137024419A 2011-02-14 2012-02-14 4-히드록시부티르산 중수소화 유사체 Active KR101976218B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161442451P 2011-02-14 2011-02-14
US61/442,451 2011-02-14
US201161484296P 2011-05-10 2011-05-10
US61/484,296 2011-05-10
PCT/US2012/024974 WO2012112492A1 (en) 2011-02-14 2012-02-14 4-hydroxybutyric acid deuterated analogs

Publications (2)

Publication Number Publication Date
KR20140008391A KR20140008391A (ko) 2014-01-21
KR101976218B1 true KR101976218B1 (ko) 2019-05-07

Family

ID=46672903

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137024419A Active KR101976218B1 (ko) 2011-02-14 2012-02-14 4-히드록시부티르산 중수소화 유사체

Country Status (10)

Country Link
US (5) US8759394B2 (OSRAM)
EP (1) EP2675771B1 (OSRAM)
JP (2) JP2014513046A (OSRAM)
KR (1) KR101976218B1 (OSRAM)
CN (1) CN103370289B (OSRAM)
BR (1) BR112013020620A2 (OSRAM)
ES (1) ES2804540T3 (OSRAM)
IL (1) IL227754B (OSRAM)
MX (1) MX355742B (OSRAM)
WO (1) WO2012112492A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010239244B2 (en) 2009-04-23 2014-02-27 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
MX377251B (es) 2010-03-24 2025-03-07 Jazz Pharmaceuticals Inc Star Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
BR112013020620A2 (pt) 2011-02-14 2016-10-04 Concert Pharmaceuticals Inc análogos de ácido 4-hidroxibutírico
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CN113061089A (zh) 2015-09-23 2021-07-02 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
CN108473411B (zh) * 2015-11-19 2022-08-12 协和发酵生化株式会社 3-羟基异戊酸的一价阳离子盐的晶体及该晶体的制造方法
KR20190028441A (ko) 2016-06-24 2019-03-18 가부시키가이샤 오츠카 세이야쿠 고죠 3-히드록시이소발레르산의 아미노산염의 결정 및 그 제조 방법
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
RU2725886C1 (ru) 2017-03-30 2020-07-07 ЭксДабл-Ю ЛЭБОРЕТРИЗ ИНК. Бициклические гетероарильные производные и их получение и применение
JP2021519276A (ja) * 2018-03-23 2021-08-10 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ−β−ヒドロキシ酪酸の重水素化類似体およびその使用
ES2947089T3 (es) 2018-09-30 2023-08-01 Xwpharma Ltd Compuestos como antagonistas del receptor histamínico 3 neuronal y usos de los mismos
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
WO2021127461A1 (en) 2019-12-20 2021-06-24 Xw Laboratories Limited Methods of synthesizing 4-valyloxybutyric acid
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11357734B2 (en) 2020-06-18 2022-06-14 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
KR20230011359A (ko) 2020-06-18 2023-01-20 엑스더블유파마 리미티드 수용성 활성 약제 성분의 제어 방출 과립화물
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
KR20230058151A (ko) 2020-10-05 2023-05-02 엑스더블유파마 리미티드 감마-하이드록시부티르산 유도체의 변형된 방출 조성물
TW202300139A (zh) 2021-03-19 2023-01-01 凱瑞康寧生技股份有限公司 γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學
CN113200853A (zh) * 2021-05-19 2021-08-03 宁波窦氏化学科技有限公司 一种制备丁二酸二醇酯的工艺方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2025137671A1 (en) * 2023-12-22 2025-06-26 Temple University-Of The Commonwealth System Of Higher Education Short chain fatty acid compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010124046A1 (en) * 2009-04-23 2010-10-28 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
ZA814854B (en) * 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
US4548716A (en) * 1984-07-25 1985-10-22 Lucas Boeve Method of producing ultrapure, pyrogen-free water
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
JP2727008B2 (ja) * 1989-02-01 1998-03-11 日本酸素株式会社 静菌化水の製造方法
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1248588B (it) * 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5840331A (en) 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
AU749638B2 (en) 1997-03-17 2002-06-27 Btg International Limited Therapeutic compositions
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ES2240163T3 (es) 1999-09-14 2005-10-16 Tepha, Inc. Utilizaciones terapeuticas de polimeros y de oligomeros a base de gamma-hidroxibutirano (ghb).
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
AU2001291173A1 (en) * 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US7727549B2 (en) 2002-07-15 2010-06-01 Alcon, Inc. Pharmaceutical compositions for otic use
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20090082380A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched rosuvastatin
ES2589915T3 (es) * 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
BR112013020620A2 (pt) 2011-02-14 2016-10-04 Concert Pharmaceuticals Inc análogos de ácido 4-hidroxibutírico

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010124046A1 (en) * 2009-04-23 2010-10-28 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Industrial and engineering chemistry, 1956, Vol.48, No.3, pp.445-454

Also Published As

Publication number Publication date
JP6692319B2 (ja) 2020-05-13
BR112013020620A2 (pt) 2016-10-04
US20160326086A1 (en) 2016-11-10
US9309182B2 (en) 2016-04-12
US10040748B2 (en) 2018-08-07
WO2012112492A1 (en) 2012-08-23
MX2013009368A (es) 2013-09-26
CN103370289B (zh) 2015-09-09
US20130012565A1 (en) 2013-01-10
EP2675771B1 (en) 2020-04-08
US20210403407A1 (en) 2021-12-30
US20140343119A1 (en) 2014-11-20
CN103370289A (zh) 2013-10-23
JP2017165747A (ja) 2017-09-21
KR20140008391A (ko) 2014-01-21
JP2014513046A (ja) 2014-05-29
US20190100484A1 (en) 2019-04-04
IL227754B (en) 2018-01-31
MX355742B (es) 2018-04-26
EP2675771A1 (en) 2013-12-25
IL227754A0 (en) 2013-09-30
US8759394B2 (en) 2014-06-24
ES2804540T3 (es) 2021-02-08

Similar Documents

Publication Publication Date Title
KR101976218B1 (ko) 4-히드록시부티르산 중수소화 유사체
US11939285B2 (en) 4-hydroxybutyric acid analogs
US20150210624A1 (en) Deuterated 4-hydroxybutyric acid analogs
CA2740247C (en) 4-hydroxybutyric acid analogs
HK1195054B (en) 4-hydroxybutyric acid deuterated analogs
AU2014200986A1 (en) 4-hydroxybutyric acid analogs
HK1167641B (en) 4-hydroxybutyric acid analogs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130913

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170206

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180220

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181223

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180220

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20181223

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180720

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170206

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20190206

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190122

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20181223

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20180720

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170206

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190430

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190430

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220411

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230413

Start annual number: 5

End annual number: 5